JP2025513289A - ファルネソイドｘ受容体アゴニストの使用 - Google Patents

ファルネソイドｘ受容体アゴニストの使用 Download PDF

Info

Publication number
JP2025513289A
JP2025513289A JP2024561602A JP2024561602A JP2025513289A JP 2025513289 A JP2025513289 A JP 2025513289A JP 2024561602 A JP2024561602 A JP 2024561602A JP 2024561602 A JP2024561602 A JP 2024561602A JP 2025513289 A JP2025513289 A JP 2025513289A
Authority
JP
Japan
Prior art keywords
patient
compound
pharma
score
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024561602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513289A5 (enExample
Inventor
トーマス カポッツァ，
Original Assignee
インターセプト ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターセプト ファーマシューティカルズ， インコーポレイテッド filed Critical インターセプト ファーマシューティカルズ， インコーポレイテッド
Publication of JP2025513289A publication Critical patent/JP2025513289A/ja
Publication of JP2025513289A5 publication Critical patent/JP2025513289A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024561602A 2022-04-21 2023-04-21 ファルネソイドｘ受容体アゴニストの使用 Pending JP2025513289A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263333287P 2022-04-21 2022-04-21
US63/333,287 2022-04-21
US202263381752P 2022-10-31 2022-10-31
US63/381,752 2022-10-31
PCT/US2023/019448 WO2023205447A2 (en) 2022-04-21 2023-04-21 Uses of farnesoid x receptor agonists

Publications (2)

Publication Number Publication Date
JP2025513289A true JP2025513289A (ja) 2025-04-24
JP2025513289A5 JP2025513289A5 (enExample) 2026-04-28

Family

ID=88420596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024561602A Pending JP2025513289A (ja) 2022-04-21 2023-04-21 ファルネソイドｘ受容体アゴニストの使用

Country Status (10)

Country Link
US (1) US20250288600A1 (enExample)
EP (1) EP4511012A2 (enExample)
JP (1) JP2025513289A (enExample)
KR (1) KR20250006156A (enExample)
CN (1) CN119136794A (enExample)
AU (1) AU2023257308A1 (enExample)
CA (1) CA3249500A1 (enExample)
IL (1) IL315941A (enExample)
MX (1) MX2024012966A (enExample)
WO (1) WO2023205447A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4611888A1 (en) * 2022-10-31 2025-09-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3777863A1 (en) * 2014-09-12 2021-02-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EP3426348B1 (en) * 2016-03-11 2021-05-05 Intercept Pharmaceuticals, Inc. 3-desoxy derivative and pharmaceutical compositions thereof
JP7224307B2 (ja) * 2017-06-23 2023-02-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体の調製のための方法及び中間体

Also Published As

Publication number Publication date
KR20250006156A (ko) 2025-01-10
CN119136794A (zh) 2024-12-13
CA3249500A1 (en) 2023-10-26
WO2023205447A2 (en) 2023-10-26
IL315941A (en) 2024-11-01
US20250288600A1 (en) 2025-09-18
EP4511012A2 (en) 2025-02-26
MX2024012966A (es) 2024-11-08
WO2023205447A3 (en) 2024-04-04
AU2023257308A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
JP5094384B2 (ja) Ｆｘｒリガンドを使用する線維症の処置
Charlton et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease
JP2021063088A (ja) 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
Trauner et al. Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC
JP2020147585A (ja) 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
Bonder et al. Prevalence of primary biliary cirrhosis–autoimmune hepatitis overlap syndrome
Polyzos et al. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease
CA3125341A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2023078435A1 (zh) 叶酸在预防、诊断和治疗遗传性、感染性或过敏性疾病中的应用
JP2025513289A (ja) ファルネソイドｘ受容体アゴニストの使用
Díaz et al. Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease
WO2024097247A1 (en) Uses of farnesoid x receptor agonists
Matsuo Fluorescein angiographic features of tubulointerstitial nephritis and uveitis syndrome
US20230405078A1 (en) Detection and treatment of intestinal fibrosis
CN115605198A (zh) 脂肪性肝病的治疗药
Pagán et al. Budesonide combined with ursodeoxycholic acid in primary biliary cirrhosis with advanced liver damage
Pluimakers Late metabolic consequences of childhood cancer
HK40080642A (en) Therapeutic agent for fatty liver disease
Lithgow C-reactive protein, an inflammation marker, in nipple aspirate fluid: Relation to breast cancer risk, body mass index, lipids and carotenoids
Pirenne et al. “PROPE” TOLERANCE AFTER INTESTINAL TRANSPLANTATION IN MAN.
François et al. Late-breaking abstracts
Payance et al. Does Haemodynamic or Clinical Rebound Exist in patients with Cirrhosis after Abrupt Interruption of Beta-blockers?
Grebe et al. DIAGNOSTIC WORKUP OF HEPATOCELLULAR CARCINOMA PRIOR TO LIVER TRANSPLANTATION: SIGNIFICANCE OF COMPUTERIZED TOMOGRAPHY
Reidy et al. PHYSICAL AND OCCUPATIONAL REHABILITATION BEFORE AND AFTER INTESTINAL TRANSPLANTATION
Kobayashi et al. AUGMENTATION OF HEME OXYGENASE-1 EXPRESSION ON THE GRAFT IMMEDIATELY AFTER IMPLANTATION IN ADULT LIVING DONOR LIVER TRANSPLANTATION

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260420